keyword
epidemiolog
hepat
e
immun
immunocompromis
patient
hepat
e
viru
hev
common
caus
acut
viral
hepat
worldwid
origin
consid
restrict
human
clear
hev
hevlik
virus
sever
anim
reservoir
complex
ecolog
genet
divers
exemplifi
recent
discoveri
hev
dromedari
previous
underestim
reservoir
zoonot
virus
prior
emerg
middl
east
respiratori
syndrom
coronaviru
zoonot
foodborn
transmiss
pig
feral
anim
wild
boar
increas
import
rapidli
industri
countri
asia
pacif
region
zoonot
hepat
e
infect
particular
relev
increas
popul
live
immunosuppress
due
risk
chronic
hepat
e
patient
fortun
major
stride
made
recent
manag
chronic
hepat
e
patient
furthermor
effect
vaccin
also
avail
promis
better
control
hepat
e
burden
near
futur
review
highlight
major
recent
develop
epidemiolog
treatment
prevent
hepat
e
hepeviru
within
famili
hepevirida
nonenvelop
viru
measur
approxim
nm
diamet
singl
strand
posit
sens
rna
genom
hev
compris
three
open
read
frame
orf
encod
nonstructur
protein
includ
methyltransferas
proteas
helicas
rnadepend
rna
polymeras
encod
capsid
protein
enabl
viru
cell
entri
contain
target
neutral
antibodi
encod
phosphoryl
protein
import
viru
releas
estim
million
hepat
e
infect
worldwid
everi
year
make
common
caus
acut
viral
hepat
region
includ
hong
kong
hev
infect
silent
individu
symptomat
usual
produc
selflimit
icter
ill
howev
progress
sever
fulmin
liver
failur
may
occur
certain
highrisk
group
pregnant
women
elderli
patient
underli
liver
diseas
although
one
serotyp
four
major
hev
genotyp
capabl
infect
human
current
recogn
hev
genotyp
found
human
account
hepat
e
develop
world
transmiss
occur
fecalor
rout
via
contamin
waterway
hev
genotyp
found
swine
anim
across
world
sporad
infect
human
industri
countri
via
foodborn
rout
humantohuman
spread
develop
countri
limit
bloodborn
transmiss
via
blood
product
deriv
virem
donor
addit
genotyp
clinic
import
sever
novel
hevlik
virus
discov
varieti
anim
specimen
similar
overal
genom
organ
differ
term
total
genom
length
posit
respect
junction
expand
rang
anim
reservoir
hev
pig
domest
pig
import
reservoir
hev
genotyp
capabl
infect
human
first
isol
swine
specimen
unit
state
also
discov
larg
proport
herd
across
north
american
midwest
seroposit
hev
find
echo
studi
swine
popul
across
world
anoth
genotyp
clinic
import
identifi
pig
taiwan
genotyp
subsequ
found
enzoot
china
japan
also
recent
report
swine
popul
autochthon
human
infect
europ
hev
infect
gener
affect
young
pig
subclin
given
high
fecal
viral
load
prolong
period
viru
shed
stool
transmiss
pig
like
fecalor
hev
genotyp
also
found
number
anim
speci
significantli
anim
hunt
game
meat
deer
wild
boar
close
relat
strain
also
detect
mongoos
rabbit
rat
addit
discoveri
number
novel
hevlik
virus
increas
varieti
anim
brought
light
immens
ecolog
divers
hev
result
call
expans
reorgan
current
classif
system
hepevirida
famili
exampl
recent
work
dromedari
camel
led
discoveri
novel
genotyp
hev
also
first
descript
differ
genom
featur
differ
strain
hev
geograph
distribut
terrestri
anim
reservoir
hev
summar
tabl
fig
zoonot
transmiss
human
well
establish
variou
line
evid
increas
hev
seropreval
swine
handler
compar
gener
public
provid
indirect
evid
subclin
infect
due
contact
infect
anim
nonhuman
primat
success
infect
hev
genotyp
experiment
set
prove
feasibl
zoonot
infect
epidemiolog
studi
outbreak
case
seri
show
histori
consumpt
uncook
deer
wild
boar
meat
shellfish
risk
factor
acquir
hepat
e
foodborn
zoonot
sourc
hypothesi
support
high
sequenc
similar
hev
gene
sequenc
patient
autochthon
hepat
e
anim
sourc
region
rna
frequent
detect
meat
product
origin
pig
feral
anim
sold
human
consumpt
local
studi
hong
kong
pig
liver
sampl
posit
hev
rna
sequenc
ident
human
case
region
highlight
risk
acquir
hepat
e
consumpt
food
pig
liver
conge
common
delicaci
region
homogen
contamin
meat
success
use
infect
pig
demonstr
hev
rna
form
part
fulli
viabl
infecti
particl
deserv
special
mention
recent
detect
rna
shellfish
may
emerg
indirect
vehicl
zoonot
transmiss
highlight
health
risk
consum
undercook
bivalv
filter
feed
waterb
suppli
runoff
contamin
swine
excreta
viscera
due
rapid
industri
improv
sanitari
condit
mani
part
east
asia
zoonot
hev
transmiss
assum
increas
import
result
genotyp
switch
develop
countri
asia
although
hev
genotyp
frequent
detect
pig
anim
human
diseas
still
occur
personeperson
spread
howev
even
set
zoonot
transmiss
may
account
hepat
e
case
although
rat
rabbit
mongoos
popul
known
harbor
hev
strain
close
relat
human
pathogen
hev
strain
role
caus
zoonot
human
hepat
e
unclear
stage
potenti
rat
harbor
infecti
hev
particular
concern
due
close
proxim
urban
human
dwell
possibl
role
dromedari
camel
hev
although
studi
shown
hev
commonest
caus
acut
hepat
dubai
sequenc
inform
hev
strain
involv
avail
genom
studi
hev
dubai
patient
reveal
import
dromedari
possibl
sourc
hev
middl
east
ubiquit
presenc
variou
anim
reservoir
direct
impact
clinic
practic
patient
present
acut
hepat
ask
recent
consumpt
undercook
pork
shellfish
game
meat
contact
swine
effluent
explor
transfus
blood
product
also
potenti
rout
acquisit
hepat
e
patient
report
exposur
test
hev
immunoglobulin
rna
besid
expedit
diagnosi
epidemiolog
clue
could
also
enabl
treatment
certain
group
patient
risk
chronic
hepat
e
infect
see
facilit
outbreak
investig
although
zoonot
hev
case
sporad
point
sourc
foodborn
hev
outbreak
well
document
figur
geograph
distribut
hepat
e
viru
novel
hevlik
virus
terrestri
anim
pig
wild
boar
deer
definit
implic
zoonot
transmiss
human
role
mongoos
rat
rabbit
caus
human
hepat
e
unclear
acquisit
hev
use
porcin
deriv
medic
product
heparin
insulin
coagul
factor
never
convincingli
demonstr
remain
theoret
possibl
given
ubiqu
hev
swine
popul
zoonot
potenti
increas
number
newli
discov
hev
genotyp
unclear
stage
virus
demonstr
high
host
specif
interspeci
transmiss
hev
seldom
achiev
experiment
infect
set
also
appear
rare
natur
howev
possibl
alway
consid
patient
present
acut
hepat
contact
exot
anim
consumpt
meat
novel
hev
highli
diverg
nucleotid
sequenc
perform
convent
serolog
diagnost
test
uncertain
howev
use
panhepevir
consensu
primer
still
enabl
case
recogn
increas
use
unbias
next
gener
sequenc
randomli
amplifi
nucleic
acid
extract
part
metagenom
analysi
patient
specimen
may
also
enabl
detect
novel
hev
clinic
set
understand
reservoir
rout
transmiss
enabl
institut
specif
prevent
measur
public
health
educ
avoid
undercook
meat
seafood
remain
singl
import
prevent
measur
evid
suggest
boil
meat
stirfri
high
heat
minut
inactiv
infecti
viral
particl
patient
face
immunosuppress
remind
dietari
practic
given
potenti
sever
sequela
hepat
e
group
vaccin
attract
altern
costeffect
populationwid
usag
remain
evalu
hev
control
level
anim
husbandri
remain
assess
measur
hous
swine
barrier
condit
regular
screen
hev
rna
propos
herd
rais
provid
xenotranspl
medic
product
howev
method
like
inhuman
commerci
impract
swine
rais
food
industri
increas
public
recognit
risk
foodborn
hepat
e
hev
control
solut
step
meat
product
chain
must
sought
hepat
e
previous
consid
caus
acut
hepat
progress
chronic
carriag
howev
percept
chang
public
case
seri
solid
organ
transplant
recipi
acut
autochthon
infect
southern
franc
author
show
eight
patient
progress
chronic
hepat
character
mild
derang
liver
enzym
persist
detect
hev
rna
serum
stool
month
delayedabs
hev
seroconvers
histolog
featur
chronic
viral
hepat
dens
lymphocyt
periport
infiltr
piecem
necrosi
chronic
hev
carriag
describ
liver
kidney
pancrea
heartlung
stem
cell
transplant
recipi
autochthon
hepat
e
infect
posttranspl
set
appear
uncommon
screen
studi
hev
rna
sera
liver
transplant
recipi
show
hepat
e
infect
preval
europ
howev
approxim
half
patient
acut
autochthon
hepat
e
posttranspl
period
progress
chronic
infect
convers
rate
report
one
french
case
seri
preval
chronic
hepat
e
among
transplant
recipi
asian
countri
unknown
alarmingli
signific
proport
chronic
hev
carrier
rapidli
progress
cirrhosi
portal
hypertens
inabl
clear
hev
viremia
directli
relat
degre
immunosuppress
patient
time
infect
therefor
infect
occur
shortli
transplant
reject
episod
patient
low
total
lymphocyt
count
like
progress
chronic
infect
use
tacrolimu
oppos
ciclosporin
also
known
risk
factor
chronic
hev
posttranspl
patient
hev
immunoglobulin
g
seroposit
prior
transplant
exclud
patient
reinfect
posttransplant
reinfect
report
progress
chronic
infect
reactiv
endogen
hev
poststem
cell
transplant
also
report
chronic
hev
infect
also
rare
describ
two
immunocompromis
patient
group
e
hiv
carrier
patient
hematolog
malign
littl
data
avail
appear
chronic
hev
coinfect
hiv
posit
patient
low
count
cellsml
produc
sever
liver
injuri
rapid
progress
cirrhosi
awar
recognit
entiti
crucial
specif
therapi
avail
halt
diseas
progress
see
exact
preval
chronic
hev
carriag
hiv
carri
popul
remain
delin
descript
chronic
hev
patient
leukemia
lymphoma
chemotherapi
limit
case
report
although
may
reflect
condit
uncommon
underdiagnosi
due
lack
awar
among
clinician
possibl
mani
caus
liver
function
derang
transplant
patient
includ
drug
cytomegaloviru
diseas
graft
reject
graft
versu
host
diseas
etc
hepat
e
often
consid
list
differenti
physician
even
hepat
e
consid
inappropri
diagnost
strategi
may
result
diagnosi
miss
enzym
immunoassay
base
test
frequent
use
exclus
acut
hepat
e
immunocompet
patient
unreli
diagnosi
immunocompromis
patient
due
variabl
timefram
seroconvers
hev
revers
transcriptasepolymeras
chain
reaction
blood
stool
specimen
consid
immunocompromis
patient
derang
liver
function
test
unknown
etiolog
although
three
group
immunocompromis
patient
identifi
risk
chronic
hepat
e
far
clinician
may
also
face
condit
patient
profound
chronic
immunosuppress
e
especi
autoimmun
condit
system
lupu
erythematosu
case
chronic
hev
infect
relat
consumpt
undercook
pork
case
mussel
game
meat
blood
product
transfus
potenti
import
mode
acquisit
well
unit
kingdom
recent
estim
one
donor
hepat
e
viremia
time
donat
associ
acut
hepat
well
persist
infect
immunocompromis
recipi
rais
question
need
screen
blood
product
hev
rna
prior
transfus
group
risk
persist
infect
given
asymptomat
mild
cours
major
case
hepat
e
infect
gener
popul
institut
gener
screen
blood
product
hev
prior
transfus
requir
thorough
costeffect
analysi
transmiss
hev
via
infect
liver
graft
report
case
chronic
hev
report
europ
america
unsurprisingli
nearli
hev
isol
patient
belong
genotyp
predomin
hev
genotyp
area
first
case
chronic
infect
recent
describ
patient
china
potenti
establish
chronic
infect
human
be
unknown
wider
avail
molecular
diagnosi
sequenc
close
surveil
transplant
recipi
hiv
posit
patient
develop
countri
undertaken
defin
risk
compar
summari
clinic
featur
diagnosi
acut
chronic
form
hepat
e
present
tabl
immunocompromis
patient
diagnos
hepat
e
close
follow
regular
monitor
blood
hev
rna
viral
load
liver
function
test
liver
stiff
delay
manag
persist
viremia
minim
due
potenti
rapid
onset
irrevers
liver
injuri
reduct
immunosuppress
consid
patient
persist
hev
viremia
month
viremia
still
persist
immunosuppress
otherwis
essenti
specif
antivir
treatment
immunomodul
consid
immunomodul
pegyl
interferon
use
success
liver
transplant
recipi
chronic
hepat
e
wider
use
transplant
set
discourag
due
risk
graft
reject
cours
pegyl
interferon
use
treat
hiv
posit
patient
chronic
hev
accumul
evid
use
guanosin
analogu
ribavirin
persist
virem
patient
fail
trial
immunosuppress
reduct
recent
case
seri
involv
postsolid
organ
transplant
patient
chronic
hepat
e
ribavirin
monotherapi
median
month
result
sustain
virolog
respons
defin
studi
clearanc
viremia
month
treatment
patient
liver
function
test
normal
patient
patient
develop
recurr
viremia
achiev
sustain
virolog
respons
retreat
ribavirin
month
anemia
import
treatment
relat
side
effect
six
month
ribavirin
monotherapi
also
use
anecdot
hiv
patient
chronic
hev
clearanc
viremia
improv
liver
stiff
liver
function
test
effect
antiretrovir
therapi
facilit
clearanc
hev
viremia
unknown
patient
delay
diagnosi
present
liver
cirrhosi
may
consid
liver
transplant
howev
reactiv
hev
liver
transplant
chronic
hepat
e
describ
result
recurr
hepat
liver
graft
therefor
virolog
clearanc
ribavirin
consid
consid
transplant
patient
group
manag
immunocompromis
patient
diagnos
hepat
e
summar
fig
ribavirin
anecdot
use
treatment
acut
hepat
e
immunocompet
hiv
posit
patient
unclear
whether
patient
recov
due
ribavirin
use
result
natur
cours
diseas
gener
accept
acut
hepat
follow
hev
infect
aris
immunopatholog
rather
direct
viral
cytopath
effect
therefor
biolog
role
ribavirin
modul
diseas
progress
unclear
control
trial
requir
defin
role
ribavirin
treatment
patient
acut
hepat
e
ribavirin
prophylaxi
describ
postexposur
prophylaxi
viral
hemorrhag
fever
virus
rais
intrigu
possibl
ribavirin
postexposur
prophylaxi
sequest
outbreak
set
refuge
camp
militari
subsequ
analysi
vaccin
popul
protect
extend
year
vaccin
independ
hepat
b
carrier
statu
vaccin
well
toler
also
appear
safe
pregnanc
preliminari
analysi
interestingli
major
patient
placebo
group
develop
clinic
hepat
e
genotyp
hev
rna
sequenc
support
previou
anim
studi
found
genotyp
base
vaccin
highli
cross
protect
zoonot
genotyp
signific
find
encourag
trial
vaccin
area
predomin
vaccin
appear
highli
promis
question
remain
durat
protect
efficaci
outbreak
set
immunogen
young
children
immunogen
efficaci
immunocompromis
patient
phase
iv
trial
current
progress
involv
individu
age
year
address
effect
vaccin
elderli
recipi
group
risk
sever
zoonot
hev
infect
hev
vaccin
also
shown
highli
immunogen
rabbit
confer
protect
rabbit
hev
vaccin
found
effect
block
transmiss
swine
popul
anim
vaccin
may
effect
intervent
reduc
zoonot
hepat
e
develop
countri
rhev
vaccin
anoth
capsid
antigen
base
purifi
polypeptid
vaccin
produc
insect
cell
line
infect
recombin
baculoviru
vector
vaccin
found
safe
effect
phase
ii
trial
involv
hev
seroneg
armi
recruit
nepal
predomin
assess
vaccin
pend
light
evid
hev
vaccin
may
offer
healthi
adult
risk
acquir
hepat
e
popul
includ
resid
travel
endem
area
vaccin
efficaci
outbreak
set
endem
area
pediatr
popul
immunocompromis
patient
requir
studi
better
understand
hev
come
new
challeng
improv
sanit
facil
clear
difficult
achiev
solut
hepat
e
control
resourcepoor
set
roadmap
autochthon
foodborn
diseas
control
develop
countri
less
clear
effect
hev
control
meat
product
chain
take
major
industri
initi
may
way
forward
sustain
control
autochthon
hepat
e
need
screen
blood
product
hev
rna
current
debat
gener
consider
public
interest
refin
treatment
paradigm
acut
chronic
hepat
e
requir
genet
basi
reduc
viral
ribavirin
suscept
defin
patient
fail
ribavirin
therapi
altern
favipiravir
explor
case
ribavirin
treatment
failur
chronic
hepat
e
patient
final
polit
resourc
mobil
requir
export
effect
safe
vaccin
area
requir
ongo
character
novel
anim
hev
genotyp
import
due
possibl
virus
undertak
speci
jump
caus
human
infect
futur
tsareva
